Vuong Trieu

Publications : 0
Aldex : 0
H-index : 0
Citations : 0


Cancers, Vol. 15, Pages 1676: High Intra Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma

Fatih M. Uckun, Vuong Trieu et 2 al.

Mar 9, 2023 in Cancers
Cancers, Vol. 15, Pages 1676: High Intra Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma Cancers doi: 10.3390/cancers15061676 Authors: Fatih M. Uckun Sanjive Qazi Vuong Trieu Here, we report that tumor samples from newly diagnosed pediatric diffuse intrinsic pontine glioma (DIPG) patients express significantly hi...

A Study to Evaluate the Safety and Efficacy of OT-101 plus Artemisinin in Hospitalized COVID-19 Subjects

Marcelo Bacci, Vuong Trieu et 2 al.

Mar 1, 2021 in
Primary Objective is to evaluate the safety and efficacy of OT-101+Artemisinin when used in combination with standard of care (SoC) in hospitalized COVID 19 subjects versus SoC+ Artemisinin+Placebo.


Chapter 9:Nanodelivery Strategies in Breast Cancer Chemotherapy

Vuong Trieu, Larn Hwang et 2 al.

Jan 1, 2016
Taxanes (paclitaxel (PTX)) and anthracyclines are important in the treatment of breast cancer, both in the adjuvant and metastatic settings. Combination therapy with anthracyclines and PTX has been shown to produce significant improvements in survival, but can be associated with significant side effects. By altering the plasma pharmacokinetics and tissue distribution, new anthracycline and PTX nan...


Chemoprotection by VEGF: Rationale for combination nab-paclitaxel and bevacizumab

Vuong Trieu, N. Desai et 3 al.

Jan 1, 2007 in Journal of Clinical Oncology
1064 Background : Nanoparticle albumin-bound (nab-) paclitaxel (ABX) has shown greater efficacy and less toxicity than solvent-based paclitaxel (TAX) in xenograft models and clinical trials. The goal of this study was to determine the effects of VEGF modulation in human MDA-MB-231 breast tumor cell line and the effects of ABX and VEGF-neutralizing antibody bevacizumab (AVA) combination on the gro...


Abstract 3742: Treatment with trabedersen, an anti-TGF-beta 2 antisense, primed tumors to subsequent chemotherapies

Larn Hwang, Vuong Trieu et 3 al.

Jan 1, 2016 in Cancer Research
Background : Overexpression of transforming growth factor-beta 2 (TGF-β2) is associated with poor prognosis and plays a key role in malignant progression of various tumors by inducing proliferation, metastasis, angiogenesis and immunosuppression. Previously reported P-001 trial of Trabedersen - Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overpro...


Proof of concept for the clinical utility of a convection enhanced delivery platform for immuno-oncology drugs against brain tumors

Fatih M. Uckun, Vuong Trieu et 2 al.

Jan 1, 2019
Here we present a post-hoc analysis of the long-term follow-up data for the Phase IIB study NCT00431561 regarding the clinical activity of the TGFbeta2-specific RNA therapeutic OT101/Trabedersen in recurrent/refractory WHO Grade 3 anaplastic astrocytoma (R/R AA) patients. OT101 was administered intratumorally by continuous infusion via CEDOT for 5 consecutive months to 27 recurrent/refractory WHO ...


Evaluation of a nonbiologic nanoparticle form of paclitaxel in metastatic pancreatic cancer.

Kouros Motamed, Vuong Trieu et 3 al.

Jan 1, 2017
e15076 Background : The (nab-Pac)/Gemcitabine (Gem) combination has recently been shown to impart a significant survival advantage over Gem alone in patients with metastatic pancreatic cancer. The g...